Researchers found that general surgery patients with Type 2 diabetes undergoing basal bolus treatment with insulin glargine plus insulin glulisine had better glycemic control and fewer complications compared with those given sliding scale regular insulin. The study showed that 55% of 104 basal bolus patients had glucose readings of less than 140 mg/dL compared with 31% of 107 patients in the SSI group.

Full Story:
Endocrine Today

Related Summaries